

[Members Login](#)[XING Forums](#)[Search](#)[Contact Us](#)[News Channels](#)[Home](#)**CONFERENCES & EVENTS**

[Pharmaceutical & Medical Device Risk-Sharing & Value-Based Pricing and Reimbursement Schemes](#)
[2nd Annual Best Practice in Clinical Site Selection & Management](#)
[Sharper and More Innovative eMarketing Strategies](#)
[Be at Med-e-Tel 2009 to Meet a Highly Qualified eHealth Audience](#)

[Read more...](#)**RESEARCH & DEVELOPMENT**

[Key Demographics and Behaviors for Consumers Using Search Engines for Online Health and Pharma Info](#)
[The Future of Mobile Health: Mobile Adoption, mHealth and Mobile Marketing](#)
[Manhattan Research Releases Top Pharma Brand Product Sites by Consumer Satisfaction](#)
[European Medicines Agency welcomes continuation of D:A:D study](#)

[Read more...](#)**WELCOME**

World Pharma News is one of the world's leading web-based publications in the fields of pharmaceutical news coverage and dissemination. Our subscribers are continuously informed about the latest and most prominent Research and Development, Conferences and Events, Financial, Corporate and Clinical Trials topics.

 [World Pharma News RSS Channel](#)
 [Subscribe to World Pharma News by Email](#)
 (powered by Google)

PharmaNews.eu, an advanced web based news engine, addressed to the European pharmaceutical domain, has been launched. The project was developed to directly connect, promote and disseminate the European pharmaceutical news...
 For further information and advanced RSS channels, please visit <http://www.pharmanews.eu>

PHARMANEWS.EU**PHARMACEUTICAL COMPANIES**

[[A](#) | [B](#) | [C](#) | [D](#) | [E](#) | [F](#) | [G](#) | [H](#) | [I](#) | [J](#) | [K](#) | [L](#) | [M](#) | [N](#) | [O](#) | [P](#) | [Q](#) | [R](#) | [S](#) | [T](#) | [U](#) | [V](#) | [W](#) | [X](#) | [Z](#)]

HemCon Announces Further Successful Results from Live Nail Infection Anti-Fungal Study

Thursday, 12 February 2009

HemCon Medical Technologies, Inc. has announced results from an independent study investigating the time required to successfully treat fungal infected human nails which is a leading cause of Onychomycosis. The studies were conducted as part of HemCon's continued program of development for a formulation based on its newest proprietary platform technology. The Onychomycosis treatment, Mycosinate™ (formerly known as compound A31S), is available for commercial license and provides a controlled release broad spectrum antimicrobial agent to fight infection.

The independent testing of Mycosinate™ for the treatment of Onychomycosis was performed by MedPharm Ltd, UK using fungal infected human nails under conditions that simulate the clinical situation. This system tests the formulations ability to penetrate the nail and kill the T. Rubrum fungal infection on human nails over a period of time. The results observed indicated complete kill of the fungal infection with the active Mycosinate™ formulation in less than 14 days. Subsequent testing to further define the exact period of time to required kill the nail fungal infection is now under way.

Fungal nail infections affect tens of millions of people worldwide and the market size for its treatment for products is estimated at approximately US\$4 billion. It is believed that 6-8 percent of all adults will acquire a fungal nail infection, and Onychomycosis is responsible for nearly 50 percent of reported cases.

"Our third and most advanced anti-fungal study in live human nail infection, combined with earlier successes in nail penetration and human safety, affirms the exceptional promise of relief that Mycosinate™ will offer to millions of Americans afflicted with fungal nail infections," said John W. Morgan, CEO of HemCon. "HemCon will continue to offer new technologies for commercialization that promote safe, effective healing on a global scale."

About HemCon Medical Technologies Inc.

HemCon Medical Technologies Inc., is a leading global developer of advanced medical products designed to improve the standard of patient care. The company is responsible for developing the chitosan-based HemCon dressing used by thousands of military and civilian first responders and is changing wound care best practices in hospital, dental and clinical settings. In addition, HemCon is leading the charge to develop and license unique, life-saving medical advances including Lyophilized Human Plasma and Nanospider™ technologies. HemCon is headquartered in Portland, Ore., with additional commercial operations in Ireland, England, Germany and the Czech Republic. For more information, please visit www.hemcon.com.

Bookmark with:



sponsored ads

[Treating Toenail Fungus?](#)

New Fungisil is the Most Effective Toenail Fungus Solution Available.
www.Fungisil.com

[Nail Fungus Eliminated](#)

Organic Remedy Kills Nail Fungus Nail Fungus Fear Our Treatments
www.fonoils.com/nail-fungus

[CRO Services - Ophthalmol](#)

Promedica International Medical device studies since 1985.
www.promedica-intl.com

[Toenail Fungus Cures](#)

Cure Toenail fungus in 1 week Written by a well known auther.
ToenailCure.PublicHealthForums.com



Ads by Google

PHARMACEUTICAL RSS NEWS

[Abbott](#) | [Amgen](#) | [AstraZeneca](#) | [Boehringer Ingelheim](#) | [Bristol-Myers Squibb](#) | [Eli Lilly](#) | [GlaxoSmithKline](#) | [Janssen-Cilag](#) | [Johnson & Johnson](#) | [Novartis](#) | [Novo Nordisk](#) | [Pfizer](#) | [Roche](#) | [Shire](#) | [Takeda](#) | ...

 [European Commission - Pharmaceuticals](#)
 [US Food and Drug Administration](#)

Google Groups

Get all news digests delivered to your inbox, subscribe to World Pharma News Google Group.

Email:

PHARMANEWS.EU / LATEST NEWS

[Bayer Schering Pharma to invest 100 million Euro in China to build a global R&D center](#)

[Strong Fourth Quarter for Genzyme Concludes Productive Year](#)

[The Pharmaceutical Forum - Delivering for Patients](#)

[SmartCell to use plant cells as pharmaceutical factories](#)

[Bayer Schering Pharma Starts Phase III Program of New Drug](#)

Against Pulmonary Hypertension
Fresenius Medical Care's eHealth Congress
EMA Public Statement on Fee Reductions for Designated Orphan Medicinal Products
Schering-Plough Research Institute (SPRI) Invests in Early Drug [Back]
Discovery Technology
Schering-Plough Reports Financial Results for 2008 Fourth Quarter, Full Year
European Commission Clears Acquisition of Zentiva NV by sanofi-aventis

[Next >](#)

W LINK IT!

sponsored ads

Cure Nail Fungus

Stop your nail fungus problems. Fast Results. Act Now.
 Funga-Nail.com

Vancouver Toenails

Local foot & ankle treatment clinic Your aching feet in gentle hands
 familyfootcarewa.com

CTM recruits patients

No nonsense patient recruitment. No bloated fees. 1-888-615-8811.CTM
 ClinicalTrialMedia.com

MOST READ - PRODUCT

Merck Provides Update on Status of Supplemental Biologics License Applications (sBLA) for GARDASIL®
 Study Shows IRESSA™ (Gefitinib) Is As Effective As Docetaxel In Pre-Treated Advanced NSCLC
 Lundbeck in-licenses Circadin®, a drug approved for the treatment of primary insomnia
 GlaxoSmithKline receives approval for Atriance® (nelarabine) in Europe
 Lipitor Demonstrated Significant Improvement or Stabilization of Kidney Function
 Prix Galien USA Names HUMIRA Best Biotechnology Product
 Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance - ATRIPLA®
 Galvus®, a new oral treatment for type 2 diabetes, receives positive opinion
 Novel oral anticoagulant Pradaxa® (dabigatran etexilate) approved by the European Commission
 Novartis withdraws its application to extend the marketing authorisation for Zometa

sponsored ads

Advanced Fungus Treatment
 Board Certified Podiatrist Cure for Thick, Yellow, Nails. (Fungus)



Nail Fungus Treatment
 Organic Nail Fungus Treatment Guaranteed Results Or Money Back.

Ads by Google



Ads by Google

PRODUCT

CLINICAL TRIALS

CORPORATE

FINANCIAL

HemCon Announces Further Successful Results from Live Nail Infection Anti-Fungal Study
 Prasugrel Receives Unanimous Approval Recommendation from FDA Advisory Committee
 GlaxoSmithKline and Idenix Pharmaceuticals sign worldwide license agreement for IDX899
 European Commission (EC) has granted marketing authorisation for Nplate(R) (romiplostim)
 Novartis launches Extavia®, the standard-of-care for relapsing forms of multiple sclerosis

[Read more...](#)

Roche Announces Interim Results from a Phase III ATLAS Study
 Lipitor Significantly Reduced hsCRP Levels in Patients with Stable Coronary Artery Disease
 Pfizer Discontinues Global Phase III Trial of Axitinib
 Genzyme and Isis Begin New Clinical Trials of Mipomersen
 Tarceva brings new hope to patients with advanced non-small cell lung cancer

[Read more...](#)

Bayer Schering Pharma to invest 100 million Euro in China to build a global R&D center
 Pfizer to Disclose Payments to US Physicians, Healthcare Professionals and Clinical Investigators
 Pfizer and The Pfizer Foundation Recognize "World Cancer Day"
 Foundation-laying ceremony for new R&D building at Roche Basel
 Amgen's Breakaway from Cancer Initiative Expands to Help Cancer Patients

[Read more...](#)

Lundbeck to acquire US-based Ovation Pharmaceuticals, Inc.
 European Commission Clears Acquisition of Zentiva NV by sanofi-aventis
 Strong operating results for Roche in 2008
 Novartis increases dividend by 25% based on strong 2008 results
 AstraZeneca PLC Fourth Quarter and Full Year Results 2008

[Read more...](#)